|New Threads Only:|
|New Threads & Replies:|
Forum List » Guru News and Commentaries|
Guru News, Stock picks and commentaries
Eveillard’s First Eagle Seizes 45% of Pharamaceutical Company, Aradigm
Posted by: Dianne Tordillo (IP Logged)
Date: December 19, 2012 10:50AM
As of Dec. 18, investing Guru Jean-Marie Eveillard, along with his mutual fund firm, First Eagle Investment Management, has reported increasing the firm’s stake in the pharmaceutical company, Aradigm Corp. (ARDM), by 173.61 percent, according to GuruFocus Real Time Picks.
First Eagle originally started with 38 million shares, upon presenting the stock as a new buy in 2009. But after buying more chunks of Aradigm this month, the firm stands with 114 million shares of the company, representing 45.36 percent of shares outstanding.
This is the second transaction made with Aradigm since acquiring the stock; the first transaction was made Dec. 11, with a purchase of about 3.6 million shares.
With a market capitalization of $25.5 million, Aradigm is focused on the development and commercialization of drugs delivered by inhalation of the treatment of severe respiratory diseases, such as bronchiectasis, cystic fibrosis, anthrax infections and smoking cessation.
One day after First Eagle’s first transaction, Aradigm announced a private placement for $6 million, targeting two existing shareholders, First Eagle being one of them. Aradigm set out to sell 50 million of its shares of common stock, at $0.12 per share.
Proceeds from the placement will be used to further the development of the medicine, ciprofloxacin, an antibiotic used to treat different types of bacterial infections, frequently experienced by cystic fibrosis patients.
Aradigm president and CEO, Igor Gonda, stated in a press release, “We are very pleased for the support demonstrated by our shareholders in this private placement. These proceeds will enable us to further our product development and formation of partnerships for commercialization."
In Aradigm’s third quarter, the company reported lower total operating expenses due to lower clinical costs for its ciprofloxacin program. Its total revenue amounted to $0.3 million, compared to year-over-year data of $0.2 million.
By the end of the quarter, the company had cash, equivalents and short-term investments that totaled $4.1 million.
Eveillard is the only Guru who has holding of Aradigm’s stock, which is down about 6.25 percent in this morning’s trading. Currently, Aradigm is priced at $0.12 per share.
It has a P/E (ttm) ratio of 0.4 and a P/S ratio of 29.2, which is close to its three-year high.
To view his latest trades, visit Jean-Marie Eveillard’s Stock Picks. Also view his undervalued stocks, high-yield companies and top growth stocks.
About GuruFocus Real Time Picks
GuruFocus Real Time Picks alerts you of the stock purchases and sales that Gurus have made within the last two days. Follow your favorite Gurus closely with GuruFocus' Premium Membership! If you are not a Premium Member, we invite you for a 7-Day Free Trial.
Guru Discussed: Jean-Marie Eveillard: Current Portfolio, Stock Picks
Stocks Discussed: ARDM,
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.